Specific combinations of CT imaging features rather than individual findings alone may improve the accuracy of identifying ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET Representatives: Trevi senior management will be joined by key opinion leaders in ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Plus, when to see a doctor.

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...